Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

被引:79
作者
Dao, Fanny [1 ]
Schlappe, Brooke A. [1 ]
Tseng, Jill [1 ]
Lester, Jenny [2 ]
Nick, Alpa M. [3 ]
Lutgendorf, Susan K. [4 ,5 ]
McMeekin, Scott [6 ]
Coleman, Robert L. [3 ]
Moore, Kathleen N. [6 ]
Karlan, Beth Y. [2 ]
Sood, Anil K. [3 ]
Levine, Douglas A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA
[3] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol, Dept Canc Biol, Dallas, TX USA
[4] Univ Iowa, Holden Comprehens Canc Ctr, Dept Psychol & Brain Sci, Dept Obstet & Gynecol, Iowa City, IA 52242 USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Dept Urol, Iowa City, IA 52242 USA
[6] Univ Oklahoma, Dept Obstet & Gynecol, Stephenson Oklahoma Canc Ctr, Div Gynecol Oncol, Oklahoma City, OK USA
关键词
Ovarian cancer; Long-term survival; Neoadjuvant chemotherapy; Surgical cytoreduction; Outcome; Survival; PROGNOSTIC-FACTORS; CANCER; MORTALITY; SURGERY; DISEASE;
D O I
10.1016/j.ygyno.2016.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years. Methods. A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded. Results. The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57 years (range 37-84 years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144 months, 88 (46.8%) patients did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of <12 months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis. Conclusions. LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10 years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:260 / 263
页数:4
相关论文
共 50 条
  • [21] Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
    Kurman, R. J.
    ANNALS OF ONCOLOGY, 2013, 24 : 16 - 21
  • [22] Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment
    Yalcin, Ibrahim
    Meydanli, Mehmet Mutlu
    Turan, Ahmet Taner
    Taskin, Salih
    Sari, Mustafa Erkan
    Gungor, Tayfun
    Akbayir, Ozgur
    Ayhan, Ali
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (02) : 329 - 337
  • [23] Assessment of the differences in oncologic outcomes between patients with high-grade serous ovarian carcinoma and uterine serous carcinoma
    Kilic, Fatih
    Ersak, Burak
    Cakir, Caner
    Yuksel, Dilek
    Kilic, Cigdem
    Korkmaz, Vakkas
    Tokgozoglu, Nedim
    Toptas, Tayfun
    Boran, Nurettin
    Comert, Gunsu Kimyon
    Ureyen, Isin
    Tasci, Tolga
    Tekin, Ozlem Moraloglu
    Ustun, Yaprak
    Turan, Taner
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (01) : 86 - 94
  • [24] Tubal Precursor Lesions for High-Grade Serous Ovarian Carcinoma
    Mahmoud Hanafy Meleis
    Ahmed Mohammed Samy El-Agwany
    Indian Journal of Gynecologic Oncology, 2015, 13 (1)
  • [25] Extracellular vesicles display distinct glycosignatures in high-grade serous ovarian carcinoma
    Bienes, Kristina Mae
    Yokoi, Akira
    Kitagawa, Masami
    Kajiyama, Hiroaki
    Andersen, Morten-Thaysen
    Kawahara, Rebeca
    BBA ADVANCES, 2025, 7
  • [26] Differential expression of immune related genes in high-grade ovarian serous carcinoma
    Siamakpour-Reihani, Sharareh
    Cobb, Lauren Patterson
    Jiang, Chen
    Zhang, Dadong
    Previs, Rebecca A.
    Owzar, Kouros
    Nixon, Andrew B.
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 662 - 668
  • [27] Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma
    Kim, Se Ik
    Jung, Minsun
    Dan, Kisoon
    Lee, Sungyoung
    Lee, Cheol
    Kim, Hee Seung
    Chung, Hyun Hoon
    Kim, Jae-Weon
    Park, Noh Hyun
    Song, Yong-Sang
    Han, Dohyun
    Lee, Maria
    CANCERS, 2020, 12 (04)
  • [28] Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma
    Geistlinger, Ludwig
    Oh, Sehyun
    Ramos, Marcel
    Schiffer, Lucas
    LaRue, Rebecca S.
    Henzler, Christine M.
    Munro, Sarah A.
    Daughters, Claire
    Nelson, Andrew C.
    Winterhoff, Boris J.
    Chang, Zenas
    Talukdar, Shobhana
    Shetty, Mihir
    Mullany, Sally A.
    Morgan, Martin
    Parmigiani, Giovanni
    Birrer, Michael J.
    Qin, Li-Xuan
    Riester, Markus
    Starr, Timothy K.
    Waldron, Levi
    CANCER RESEARCH, 2020, 80 (20) : 4335 - 4345
  • [29] Ultrasound characteristics of early-stage high-grade serous ovarian cancer
    Suh-Burgmann, Elizabeth
    Brasic, Natasha
    Jha, Priyanka
    Hung, Yun-Yi
    Goldstein, Ruth B.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 225 (04) : 409.e1 - 409.e8
  • [30] Molecular Analysis of High-Grade Serous Ovarian Carcinoma Exhibiting Low-Grade Serous Carcinoma and Serous Borderline Tumor
    Kanno, Kosuke
    Nakayama, Kentaro
    Razia, Sultana
    Islam, Sohel Hasibul
    Farzana, Zahan Umme
    Sonia, Shahataj Begum
    Sasamori, Hiroki
    Yamashita, Hitomi
    Ishibashi, Tomoka
    Ishikawa, Masako
    Imamura, Kayo
    Ishikawa, Noriyoshi
    Kyo, Satoru
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (09) : 9376 - 9385